The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 17, 2022

Filed:

Sep. 16, 2021
Applicant:

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Inventors:

Saar Gill, Philadelphia, PA (US);

Michael Klichinsky, Philadelphia, PA (US);

Carl H. June, Merion Station, PA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 14/735 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); A61K 39/00 (2006.01); C12N 5/0786 (2010.01); C07K 19/00 (2006.01); C07K 16/30 (2006.01); A61K 35/15 (2015.01); A61K 35/14 (2015.01); A61P 35/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70517 (2013.01); A61K 35/15 (2013.01); A61K 39/001106 (2018.08); A61K 39/001112 (2018.08); A61K 39/001168 (2018.08); C07K 14/7051 (2013.01); C07K 14/7056 (2013.01); C07K 14/70535 (2013.01); C07K 16/2803 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C07K 19/00 (2013.01); C12N 5/0645 (2013.01); A61K 35/14 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/892 (2018.08); A61P 35/00 (2018.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/74 (2013.01); C12N 2510/00 (2013.01);
Abstract

The present invention includes methods and compositions for treating cancer, whether a solid tumor or a hematologic malignancy. By expressing a chimeric antigen receptor in a monocyte, macrophage or dendritic cell, the modified cell is recruited to the tumor microenvironment where it acts as a potent immune effector by infiltrating the tumor and killing the target cells. One aspect includes a modified cell and pharmaceutical compositions comprising the modified cell for adoptive cell therapy and treating a disease or condition associated with immunosuppression.


Find Patent Forward Citations

Loading…